Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171


Qualification and clinical validation of an Immunodiagnostic Assay for detecting 11 additional S. Pneumoniae Serotype- specific Polysaccharides in Human Urine.

Kalina WV, Souza V, Wu K, Giardina P, McKeen A, Jiang Q, Tan C, French R, Ren Y, Belanger K, McElhiney S, Unnithan M, Cheng H, Mininni T, Giordano-Schmidt D, Gessner BD, Jansen KU, Pride MW.

Clin Infect Dis. 2020 Feb 19. pii: ciaa158. doi: 10.1093/cid/ciaa158. [Epub ahead of print]


Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Harris SL, Tan C, Perez J, Radley D, Jansen KU, Anderson AS, Jones TR.

NPJ Vaccines. 2020 Jan 29;5:8. doi: 10.1038/s41541-019-0154-0. eCollection 2020.


Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).

Creech CB, Frenck RW, Fiquet A, Feldman R, Kankam MK, Pathirana S, Baber J, Radley D, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Open Forum Infect Dis. 2019 Dec 24;7(1):ofz532. doi: 10.1093/ofid/ofz532. eCollection 2020 Jan.


Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).

Bettinger JA, Liberator P, Halperin SA, Vaudry W, Sadarangani M, Hao L, Lambert N, Jansen KU, Anderson AS, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT).

Vaccine. 2020 Feb 18;38(8):2026-2033. doi: 10.1016/j.vaccine.2019.12.051. Epub 2020 Jan 23.


S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine.

Marshall HS, Baber J, Richmond P, Nissen M, Shakib S, Kreiswirth BN, Zito ET, Severs J, Eiden J, Gruber W, Jansen KU, Jones CH, Anderson AS.

J Infect. 2019 Dec;79(6):582-592. doi: 10.1016/j.jinf.2019.09.018. Epub 2019 Oct 1.


Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.

Thompson A, Lamberth E, Severs J, Scully I, Tarabar S, Ginis J, Jansen KU, Gruber WC, Scott DA, Watson W.

Vaccine. 2019 Sep 30;37(42):6201-6207. doi: 10.1016/j.vaccine.2019.08.048. Epub 2019 Sep 5.


A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.

Kitchin N, Remich SA, Peterson J, Peng Y, Gruber WC, Jansen KU, Pride MW, Anderson AS, Knirsch C, Webber C.

Clin Infect Dis. 2020 Jan 1;70(1):1-10. doi: 10.1093/cid/ciz153.


A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults.

Inoue M, Yonemura T, de Solom R, Yamaji M, Aizawa M, Knirsch C, Pride MW, Jansen KU, Gruber W, Webber C.

Vaccine. 2019 May 1;37(19):2600-2607. doi: 10.1016/j.vaccine.2019.03.014. Epub 2019 Apr 5.


A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.

Buurman ET, Timofeyeva Y, Gu J, Kim JH, Kodali S, Liu Y, Mininni T, Moghazeh S, Pavliakova D, Singer C, Singh S, Handke LD, Lotvin J, Prasad AK, Scully IL, Donald RGK, Jansen KU, Anderson AS.

J Infect Dis. 2019 Jun 5;220(1):105-115. doi: 10.1093/infdis/jiz062.


Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.

Vesikari T, Østergaard L, Beeslaar J, Absalon J, Eiden JJ, Jansen KU, Jones TR, Harris SL, Maansson R, Munson S, O'Neill RE, York LJ, Perez JL.

Vaccine. 2019 Mar 14;37(12):1710-1719. doi: 10.1016/j.vaccine.2018.11.073. Epub 2019 Feb 12.


Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States.

Mohamed N, Timofeyeva Y, Jamrozy D, Rojas E, Hao L, Silmon de Monerri NC, Hawkins J, Singh G, Cai B, Liberator P, Sebastian S, Donald RGK, Scully IL, Jones CH, Creech CB, Thomsen I, Parkhill J, Peacock SJ, Jansen KU, Holden MTG, Anderson AS.

PLoS One. 2019 Jan 14;14(1):e0208356. doi: 10.1371/journal.pone.0208356. eCollection 2019.


A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec.

Gilca R, De Wals P, Nolan SM, Kitchin N, Eiden JJ, Jiang Q, Jones CH, Jansen KU, Anderson AS, Pedneault L.

mSphere. 2018 Dec 5;3(6). pii: e00427-18. doi: 10.1128/mSphere.00427-18.


Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.

Thompson AR, Klein NP, Downey HJ, Patterson S, Sundaraiyer V, Watson W, Clarke K, Jansen KU, Sebastian S, Gruber WC, Scott DA, Schmöele-Thoma B.

Hum Vaccin Immunother. 2019;15(2):444-451. doi: 10.1080/21645515.2018.1533777. Epub 2018 Oct 25.


The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery.

Gurtman A, Begier E, Mohamed N, Baber J, Sabharwal C, Haupt RM, Edwards H, Cooper D, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2019;15(2):358-370. doi: 10.1080/21645515.2018.1523093. Epub 2018 Sep 27. Review.


Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response.

Dupont CD, Scully IL, Zimnisky RM, Monian B, Rossitto CP, O'Connell EB, Jansen KU, Anderson AS, Love JC.

mSphere. 2018 Aug 22;3(4). pii: e00217-18. doi: 10.1128/mSphere.00217-18.


Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides.

Pavliakova D, Giardina PC, Moghazeh S, Sebastian S, Koster M, Pavliak V, McKeen A, French R, Jansen KU, Pride M.

mSphere. 2018 Aug 8;3(4). pii: e00128-18. doi: 10.1128/mSphere.00128-18.


Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.

Tan CY, Immermann FW, Sebastian S, Pride MW, Pavliakova D, Belanger KA, Watson W, Scott DA, Sidhu M, Jansen KU, Giardina PC.

mSphere. 2018 Aug 8;3(4). pii: e00127-18. doi: 10.1128/mSphere.00127-18.


Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults.

Inoue M, Yonemura T, Baber J, Shoji Y, Aizawa M, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Hum Vaccin Immunother. 2018;14(11):2682-2691. doi: 10.1080/21645515.2018.1496764. Epub 2018 Aug 17.


From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.

Perez JL, Absalon J, Beeslaar J, Balmer P, Jansen KU, Jones TR, Harris S, York LJ, Jiang Q, Radley D, Anderson AS, Crowther G, Eiden JJ.

Expert Rev Vaccines. 2018 Jun;17(6):461-477. doi: 10.1080/14760584.2018.1483726. Epub 2018 Jun 22. Review.


The role of vaccines in fighting antimicrobial resistance (AMR).

Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2018;14(9):2142-2149. doi: 10.1080/21645515.2018.1476814. Epub 2018 Jul 9. Review.


Vaccination strategies for the prevention of meningococcal disease.

Vuocolo S, Balmer P, Gruber WC, Jansen KU, Anderson AS, Perez JL, York LJ.

Hum Vaccin Immunother. 2018 May 4;14(5):1203-1215. doi: 10.1080/21645515.2018.1451287. Epub 2018 Apr 13. Review.


Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.

McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, Claus H, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Wang X, Vuong J, Mayer LW, Pride MW, Jansen KU, Anderson AS.

mBio. 2018 Mar 13;9(2). pii: e00036-18. doi: 10.1128/mBio.00036-18.


The role of vaccines in preventing bacterial antimicrobial resistance.

Jansen KU, Knirsch C, Anderson AS.

Nat Med. 2018 Jan 9;24(1):10-19. doi: 10.1038/nm.4465. Review.


A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.

Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Prégaldien JL, Ginis J, Staerke NB, Perez JL; B1971009 and B1971016 Trial Investigators.

N Engl J Med. 2017 Dec 14;377(24):2349-2362. doi: 10.1056/NEJMoa1614474.


Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay.

Pride MW, Jansen KU.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00239-17. doi: 10.1128/CVI.00239-17. Print 2017 Nov. No abstract available.


Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study.

Scully IL, McNeil LK, Pathirana S, Singer CL, Liu Y, Mullen S, Girgenti D, Gurtman A, Pride MW, Jansen KU, Huang PL, Anderson AS.

Diabetol Metab Syndr. 2017 Oct 3;9:76. doi: 10.1186/s13098-017-0276-3. eCollection 2017.


Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B.

Gribenko A, Severina E, Sidhu MK, Jansen KU, Green BA, Matsuka YV.

Biochem Biophys Rep. 2017 Jan 5;9:193-202. doi: 10.1016/j.bbrep.2016.12.015. eCollection 2017 Mar.


Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen specific memory B cell repertoires.

Jia B, McNeil LK, Dupont CD, Tsioris K, Barry RM, Scully IL, Ogunniyi AO, Gonzalez C, Pride MW, Gierahn TM, Liberator PA, Jansen KU, Love JC.

PLoS One. 2017 Sep 14;12(9):e0183738. doi: 10.1371/journal.pone.0183738. eCollection 2017.


Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial.

Idoko OT, Mboizi RB, Okoye M, Laudat F, Ceesay B, Liang JZ, Le Dren-Narayanin N, Jansen KU, Gurtman A, Center KJ, Scott DA, Kampmann B, Roca A.

Vaccine. 2017 May 31;35(24):3256-3263. doi: 10.1016/j.vaccine.2017.04.049. Epub 2017 May 4.


Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.

Taha MK, Hawkins JC, Liberator P, Deghmane AE, Andrew L, Hao L, Jones TR, McNeil LK, O'Neill RE, Perez JL, Jansen KU, Anderson AS.

Vaccine. 2017 Mar 13;35(11):1530-1537. doi: 10.1016/j.vaccine.2017.01.066. Epub 2017 Feb 10.


Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study.

van Ravenhorst MB, Bijlsma MW, van Houten MA, Struben VMD, Anderson AS, Eiden J, Hao L, Jansen KU, Jones H, Kitchin N, Pedneault L, Sanders EAM, van der Ende A.

Clin Microbiol Infect. 2017 Aug;23(8):573.e1-573.e7. doi: 10.1016/j.cmi.2017.02.008. Epub 2017 Feb 10.


SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.

Begier E, Seiden DJ, Patton M, Zito E, Severs J, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Vaccine. 2017 Feb 22;35(8):1132-1139. doi: 10.1016/j.vaccine.2017.01.024. Epub 2017 Jan 28.


Vaccine development to prevent Staphylococcus aureus surgical-site infections.

Mohamed N, Wang MY, Le Huec JC, Liljenqvist U, Scully IL, Baber J, Begier E, Jansen KU, Gurtman A, Anderson AS.

Br J Surg. 2017 Jan;104(2):e41-e54. doi: 10.1002/bjs.10454. Review.


Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Review.


Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.

Frenck RW Jr, Creech CB, Sheldon EA, Seiden DJ, Kankam MK, Baber J, Zito E, Hubler R, Eiden J, Severs JM, Sebastian S, Nanra J, Jansen KU, Gruber WC, Anderson AS, Girgenti D.

Vaccine. 2017 Jan 5;35(2):375-384. doi: 10.1016/j.vaccine.2016.11.010. Epub 2016 Dec 1.


Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

Creech CB, Frenck RW Jr, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J.

Vaccine. 2017 Jan 5;35(2):385-394. doi: 10.1016/j.vaccine.2016.11.032. Epub 2016 Nov 17.


Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults.

Albrich WC, Pride MW, Madhi SA, Callahan J, Adrian PV, French R, van Niekerk N, Sebastian S, Souza V, Telles JN, Paranhos-Baccalà G, Jansen KU, Klugman KP.

J Clin Microbiol. 2016 Dec 28;55(1):302-312. doi: 10.1128/JCM.01573-16. Print 2017 Jan.


Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.

Harris SL, Donald RG, Hawkins JC, Tan C, O'Neill R, McNeil LK, Perez JL, Anderson AS, Jansen KU, Jones TR.

Pediatr Infect Dis J. 2017 Feb;36(2):216-223. doi: 10.1097/INF.0000000000001399.


The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease.

Luo Y, Friese OV, Runnels HA, Khandke L, Zlotnick G, Aulabaugh A, Gore T, Vidunas E, Raso SW, Novikova E, Byrne E, Schlittler M, Stano D, Dufield RL, Kumar S, Anderson AS, Jansen KU, Rouse JC.

AAPS J. 2016 Nov;18(6):1562-1575. Epub 2016 Sep 7.


Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.

Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Lee SS, Perez JL; 6108A12001 Study Investigators.

Lancet Infect Dis. 2017 Jan;17(1):58-67. doi: 10.1016/S1473-3099(16)30314-0. Epub 2016 Oct 11.


Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.

Marshall H, Nissen M, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber WC, Jansen KU, Anderson AS, Zito ET, Girgenti D.

J Infect. 2016 Nov;73(5):437-454. doi: 10.1016/j.jinf.2016.08.004. Epub 2016 Aug 9.


Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.

Dayan GH, Mohamed N, Scully IL, Cooper D, Begier E, Eiden J, Jansen KU, Gurtman A, Anderson AS.

Expert Rev Vaccines. 2016 Nov;15(11):1373-1392. Epub 2016 May 9. Review.


Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.

Green LR, Eiden J, Hao L, Jones T, Perez J, McNeil LK, Jansen KU, Anderson AS.

Methods Mol Biol. 2016;1403:445-69. doi: 10.1007/978-1-4939-3387-7_25.


Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution.

Clark SA, Lekshmi A, Lucidarme J, Hao L, Tsao H, Lee-Jones L, Jansen KU, Newbold LS, Anderson AS, Borrow R.

J Infect. 2016 Jul;73(1):63-70. doi: 10.1016/j.jinf.2016.03.012. Epub 2016 Mar 26.


Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine.

Bryan JT, Buckland B, Hammond J, Jansen KU.

Curr Opin Chem Biol. 2016 Jun;32:34-47. doi: 10.1016/j.cbpa.2016.03.001. Epub 2016 Mar 18. Review.


A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.

Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L.

Vaccine. 2016 Apr 19;34(18):2082-91. doi: 10.1016/j.vaccine.2016.03.010. Epub 2016 Mar 15.


Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection.

Anderson AS, Scully IL, Buurman ET, Eiden J, Jansen KU.

mBio. 2016 Mar 8;7(2):e00225. doi: 10.1128/mBio.00225-16.


A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.

Ostergaard L, Lucksinger GH, Absalon J, Beeslaar J, Eiden J, Jansen KU, York LJ, Quinn A, Graversen ME, Perez JL.

Vaccine. 2016 Mar 14;34(12):1465-71. doi: 10.1016/j.vaccine.2016.01.044. Epub 2016 Feb 1.


Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.

Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, Ginis J, Perez JL.

Pediatr Infect Dis J. 2016 May;35(5):548-54. doi: 10.1097/INF.0000000000001072.


Supplemental Content

Loading ...
Support Center